Loading...

News List

阿斯利康“first-in-class”口服小分子获FDA批准上市

2024-04-24


2024年4月1日,阿斯利康宣布其“first-in-class”口服小分子Voydeya(danicopan)获FDA批准,作为标准疗法补体因子C5抑制剂Ultomiris(ravulizumab)或Soliris(eculizumab)的附加疗法,用于治疗阵发性睡眠性血红蛋白尿症(PNH)成人患者的血管外溶血(EVH)状况

Pre: Nature Biotechnology | Antibody Drug Conjugators (ADCs) : ushering in a new era of precision cancer therapy

Next: Astrazeneca's "first-in-class" oral small molecule is approved by the FDA